Freestone Capital Holdings’s ARK Genomic Revolution ETF ARKG Stock Holding History
Bought
Maintained
Sold
Other funds holding ARKG
EP
Freestone Capital Holdings's ARKG Position: Q4 2021 in Review
Freestone Capital Holdings sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2021, closing a stake of 3,076 shares — an estimated $230K sold.
Freestone Capital Holdings first reported a position in ARKG in Q4 2020 and held it in 4 quarters. The position peaked at $289K in Q2 2021. 460 funds tracked by Wall St. Rank hold ARKG as of Q4 2021.
- Freestone Capital Holdings reported no remaining ARK Genomic Revolution ETF position as of Q4 2021 after selling out during the quarter.
- Freestone Capital Holdings sold 3,076 ARK Genomic Revolution ETF shares in Q4 2021, an estimated $230K.
- Freestone Capital Holdings first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 4 quarters.
- Freestone Capital Holdings's ARK Genomic Revolution ETF position peaked at $289K in Q2 2021.
- 460 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2021.
Based on Freestone Capital Holdings's 13F filing for Q4 2021, filed 14 Feb 2022.